Interim Audit ISO 9001 : 2015

Our annual Quality Management System audit took place at 12.05.2021.

Thank you to all participants for a successful audit.

General Manager: Markus Gemein

New product category available now: COVID-19/SARS-CoV-2

To support our customers, we initiated a new category group for your COVID-19/SARS-CoV-2 research.

 

For details, follow the link

NEW ! Glucose-6-Phosphate Dehydrogenase, High-Activity, Suspension

Now avaiable:

Glucose-6-Phosphate Dehydrogenase, High-Activity, Suspension
Chromatographically purified for higher specific activity. Same as Code: ZF except assayed using NAD. Phosphohexose isomerase, phosphogluconate dehydrogenase, adenylate kinase and creatine phosphokinase contaminant activities 0.02 %, 0.003 %, 0.002 % and 0.002 % respectively. A suspension in 3.7 M ammonium sulfate.

Activity: ≥ 600 NAD units per mg protein

Unit Definition: One Unit reduces one micromole of NAD per minute at 30 °C, pH 7.8, using glucose-6-phosphate as substrate.

LS004002 – 1 KU

LS004004 – 10 Ku

Bulk requests – contact us

NEW TARGATT™ CHO and HEK293 Master Cell Lines available

Applied StemCell’s (ASC) TARGATT™ technology allows site-specific, irreversible gene insertion (up to 20 kb). ASC has taken its proprietary knockin technology and integrated the system into CHO and HEK293 cells. The TARGATT™ CHO and HEK293 Master Cell Lines have displayed high integration efficiencies and medium to high levels of protein expression. These cell lines have the potential to be used for bioproduction, to establish a mammalian cell-based library for antibody screening, and to construct a naïve IgG library system.

Bronchial/Tracheal Epithelial Cells Used in New Airway Model to Evaluate Therapeutics

A Pre-clinical Model to Evaluate Therapeutics for Respiratory Infections

The current COVID-19 pandemic has highlighted the need for a robust pre-clinical model of the respiratory tract that can allow researchers to accurately and efficiently test potential therapeutic agents against emergent infections like SARS-CoV-2. Influenza and coronaviruses like SARS-CoV-2 utilize the lung and airway cells of the respiratory tract as the main entry point into the body. The authors of a recent publication utilized Lifeline’s Human Bronchial/Tracheal Epithelial Cells (HBTECs) to develop a new high throughput in vitro model with better physiological relevance than current systems that could help expedite timelines to test lifesaving therapeutics.

In addition to HBTECs, Lifeline offers a number of other healthy and diseased state lung and airway cells as well as optimized BronchiaLife™ cell culture media. Click on the links below for more information:

  • Small airway cells
  • Diseased small airway epithelial cells – asthma and COPD
  • Bronchial/tracheal epithelial cells
  • Diseased bronchial/tracheal epithelial cells – cystic fibrosis
  • Bronchial/tracheal smooth muscle cells
  • Lobar bronchial epithelial cells
  • Lung fibroblasts
  • Lung smooth muscle cells
  • Laryngeal epithelial cells
  • BronchiaLife Complete Medium Kit

PREDICT96-ALI Model Developed with Lifeline Bronchial/Tracheal Epithelial Cells

Currently, pre-clinical studies used to test therapeutics for respiratory tract infections utilize high-throughput, low-fidelity in vitro screening with human cell lines and/or low-throughput animal models, both of which are often poorly correlated to human clinical responses resulting in a large percentage of drug failures in clinical trials that extend timelines to finding a successful drug candidate. Here, we summarize research by Gard and Colleagues where they successfully developed a high throughput in vitro human primary airway epithelial cell-based model on the PREDICT96-ALI microfluidics platform that is better able to accurately predict clinical responses compared to traditional screening methods.

Lifeline’s primary HBTECs were cultured in our BronchiaLife media and then differentiated using the HBTEC-ALI differentiation media to create a pseudostratified epithelium at an air-liquid interface (ALI) in the PREDICT96-ALI platform. The polarity of the cells at the ALI is a suitable analogue of in vivo respiratory barrier tissues mimicking a range of physiologically relevant responses. The authors used the healthy baseline airway model to test the system’s permissiveness and response to viral infections using three different strains of Influenza A (IAV), the A/WSN/33 strain, and pandemic strains of H1N1 and H3N2. Infection kinetics were determined using immunofluorescence (IF) and qPCR across a range of multiplicities of infection (MOIs) and time points. And, as a proof-of-concept, viral infection kinetics for a single IAV strain in response to pre-treatment of the airway cells with an antiviral (oseltamivir) was investigated to determine if the system could qualify the efficacy of novel therapeutic compounds.

Airway cells in the PREDICT96-ALI model were shown to be permissive to viral infection as determined by IF and qPCR results where a dose-dependent increase of viral protein and RNA, respectively, is observed as MOI increased from 0.1 – 10. To evaluate the efficacy of the model to test therapeutic agents, the airway cells were treated with the antiviral oseltamivir (Tamiflu) for 2 hrs before viral inoculation (A/WSN/33 H1N1 virus) at various MOIs. Oseltamivir treatment in the PREDICT96-ALI airway model significantly reduced influenza replication, maintained barrier integrity, and had viral copy numbers comparable to those observed in a clinical setting with patients.

Taken together, these promising results demonstrate the permissiveness to infection and the potential of the PREDICT96-ALI airway model as a pre-clinical tool to evaluate potential therapies for combating respiratory infections including SARS-CoV-2 in an efficient, robust, and high-throughput manner. Additionally, compatibility with existing pharmaceutical laboratory infrastructure, convenient readouts for quality control and physiological monitoring, makes this platform suitable across many disease areas and application domains over other micro-physiological systems (MPS). The development of more accurate viral testing systems will undoubtedly aide researchers to screen potential drug treatments faster than ever before.

Tune in for the next installation of our blog featuring new research using Lifeline products and industry highlights. If you have used Lifeline products to further your research, we would love to hear from you.

CellSystems moved to a new facility

We moved to a new facility with additional office spaces and increased storage capacity.

 

Our new address:

CellSystems® GmbH

Junkersring 5

53844 Troisdorf Germany

 

RatCol® High Concentration Rat Tail Collagen

Temporarily Out of Stock

 

We are offering these two products – however, with a lower collagen concentration – as a potential option:

5153-100MG

5056-20ML

CytoSoft® – New T-25 and T-75 Flasks Substrates of Varying Rigidity

CytoSoft® T-25 and T-75 flasks provide an increased surface area for passaging cells on an in vivo-like substrate.

 

The CytoSoft® portfolio includes a broad range of formats designed for different phases of research, including:

6-well plates – Initial discovery

24 and 96-well plates – High resolution imaging / publication quality data

T-25 and T-75 flasks – Cell passaging / expansion

 

Henkel acquires epiCS® Skin Model Technology

Nov 3, 2020 Düsseldorf / Germany

Strengthening of the Phenion® Business

 

  • Attractive portfolio with strong and successful models of the human skin
  • Global dissemination of regulatory approved alternative test methods
  • Important step towards the worldwide use and distribution of alternative test methods

Henkel closed the acquisition of the skin model technology from the SkinInVitro GmbH, located in Troisdorf, Germany, effective November 2, 2020. The closing was preceded by an extended and successful technology transfer phase, which guarantees the epiCS® production at unchanged high quality. The epiCS® skin models will be manufactured as of now in the Henkel laboratories in Düsseldorf, Germany, under the Phenion® brand.

The epiCS® technology comprises, beside others, reconstructed human epidermal equivalents, which are officially approved by the OECD for assessing the skin-corrosive potential (OECD TG 431) and, since April 2019, also the skin-irritating potential of chemicals (OECD TG 439).

Under its brand Phenion®, Henkel provides biotechnologically constructed skin models to interested contract research organizations and research institutes. With the Phenion® skin models, the company offers alternative in vitro test systems which can be used not only for basic research in dermatology and cosmetic sciences, but also for the safety assessment of raw materials and finished products.

“With this acquisition we are strengthening our existing product portfolio in the field of reconstructed human tissue models,” explains Dr. Dirk Petersohn, responsible for the Phenion® brand at Henkel Beauty Care. “With the epiCS® technology we can now offer our clients tissue models which are well-suited and regulatory accepted for analyzing the skin-corrosive and irritating potential of substances. Hence, this reasonable complement of our already existing product portfolio gives us the opportunity to serve our customers even better. We are looking forward to integrating the SkinInVitro team in order to expedite together the development and distribution of alternative test methods.”

“I am pleased that our more than 20 years of experience in technology development will be continued at Henkel,” says Horst W. Fuchs, founder and owner of the SkinInVitro GmbH. “It is a unique chance for the team to become an integral part of the globally acting Henkel company and to integrate its expertise in respect of the epiCS® technology.”

Link

Advanced BioMatrix (ABM) has acquired the HyStem® line of products from Lineage Cell Therapeutics (LCT)

The TARGATT™-HEK293 Master Cell Line and Knock-in Kit was designed for fast and site-specific knock-in in HEK293 cells, using an easy-to-use gene knock-in approach. The master cell line provided in this kit contains an “attP” integrase-recognition landing pad engineered into the hH11 safe harbor locus in the genome. The kit also contains a cloning plasmid containing a corresponding “attB” sequence into which any gene of interest can be cloned (under control of the CMV promoter or a promoter-of-choice). The expression of the integrase (provided as an integrase plasmid) mediates the stable integration of the transgene into the master cell line (Figure 1). The TARGATT™ integrase technology enables highly efficient (>40 % without enrichment and ~90 % with selection), and site-specific DNA integration without disruption of internal genes. The TARGATT™-HEK293 master cell line can therefore be used for building mammalian cell libraries with site-specific, single transgene gene knock-in and uniform, stable gene expression.

Advantages of using TARGATT™ Master Cell Lines for gene knock-in:

– High efficiency Integration

– Site-specific, stable knock-in cell line generation

– Single copy gene integration into safe harbor locus

– Gene expression from an active, intergenic locus

– Low off-target integration

The TARGATT™-HEK293 master cell line and knock-in kit are suitable for research applications involving directed-evolution of proteins (vaccine development, drug screening, cell-based gene therapy), genome-wide screening, and other stable cell line generation applications. If you are interested to get your own MASTER cell line (including stem cells), please contact us to discuss your project.